Tetsuya Ishikawa

9.0k total citations · 2 hit papers
237 papers, 7.4k citations indexed

About

Tetsuya Ishikawa is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Tetsuya Ishikawa has authored 237 papers receiving a total of 7.4k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Epidemiology, 99 papers in Hepatology and 53 papers in Molecular Biology. Recurrent topics in Tetsuya Ishikawa's work include Liver Disease Diagnosis and Treatment (68 papers), Hepatitis B Virus Studies (59 papers) and Hepatitis C virus research (52 papers). Tetsuya Ishikawa is often cited by papers focused on Liver Disease Diagnosis and Treatment (68 papers), Hepatitis B Virus Studies (59 papers) and Hepatitis C virus research (52 papers). Tetsuya Ishikawa collaborates with scholars based in Japan, United States and United Kingdom. Tetsuya Ishikawa's co-authors include Shinichi Kakumu, Francis V. Chisari, Luca G. Guidotti, Robert D. Schreiber, M V Hobbs, Takaji Wakita, Masahiro Takayanagi, Kentaro Yoshioka, Yasuyuki Higashi and Kiyohiro Ando and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Tetsuya Ishikawa

224 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes

1996 907 citations Tetsuya Ishikawa et al. profile →
Detection of Hepatitis C Virus by Polymerase Chain Reaction and Response to Interferon–α Therapy: Relationship to Genotypes of Hepatitis C Virus

1992 608 citations Shinichi Kakumu, Tetsuya Ishikawa et al. profile →

Peers

Tetsuya Ishikawa

EPIDE

HEPAT

IMMUN

RHEUM

JF Schlaak Germany

Tatsuya Kanto Japan

Birke Bartosch France

Tatsuo Kanda Japan

Mei–Hsuan Lee Taiwan

Akinori Kasahara Japan

Jeffrey S. Glenn United States

Jin‐Chuan Sheu Taiwan

Ian D. McGilvray Canada

Giovanni Migliaccio Italy

JF Schlaak Germany

Tetsuya Ishikawa

3.2k ×0.9

EPIDE

2.7k ×0.8

HEPAT

1.4k ×0.8

2.7k ×1.9

IMMUN

608 ×1.1

RHEUM

Citations per year, relative to Tetsuya Ishikawa Tetsuya Ishikawa (= 1×) peers JF Schlaak

Countries citing papers authored by Tetsuya Ishikawa

Since Specialization

Citations

This map shows the geographic impact of Tetsuya Ishikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuya Ishikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuya Ishikawa more than expected).

Fields of papers citing papers by Tetsuya Ishikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsuya Ishikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuya Ishikawa. The network helps show where Tetsuya Ishikawa may publish in the future.

Co-authorship network of co-authors of Tetsuya Ishikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsuya Ishikawa. A scholar is included among the top collaborators of Tetsuya Ishikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsuya Ishikawa. Tetsuya Ishikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Imai, Norihiro, Yuki Ohsaki, Jinglei Cheng, et al.. (2025). Pathological significance of intranuclear structures in liver biopsy samples. Hepatology Research. 55(7). 1065–1074.

Honda, Takashi, Shinya Yokoyama, Kenta Yamamoto, et al.. (2023). Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet. Nutrients. 15(6). 1473–1473. 6 indexed citations

Ishizu, Yoji, Yukio Ando, Shinya Yokoyama, et al.. (2022). An improved method to assess skeletal muscle mass in patients with liver cirrhosis based on computed tomography images. Hepatology Research. 52(11). 937–946. 5 indexed citations

Kimura, Kiminori, Tatsuya Kanto, Shinji Shimoda, et al.. (2022). Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine. 80. 104069–104069. 34 indexed citations

Fujimoto, Kazushi, Wataru Shinoda, Tetsuya Ishikawa, et al.. (2021). All-atom molecular dynamics study of hepatitis B virus containing pregenome RNA in solution. The Journal of Chemical Physics. 155(14). 145101–145101. 6 indexed citations

Kuzuya, Teiji, Takanori Ito, Yoji Ishizu, et al.. (2021). Transient deterioration of albumin–bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation. Medicine. 100(31). e26820–e26820. 3 indexed citations

Kuzuya, Teiji, Masatoshi Ishigami, Takanori Ito, et al.. (2020). Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Oncology. 98(9). 621–629. 4 indexed citations

Kuzuya, Teiji, Masatoshi Ishigami, Takanori Ito, et al.. (2019). Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatology Research. 50(3). 374–381. 25 indexed citations

Kuzuya, Teiji, Masatoshi Ishigami, Yoji Ishizu, et al.. (2018). Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. Oncology. 95(2). 91–99. 14 indexed citations

10.

Shimizu, Hanako, et al.. (2017). Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report. International Cancer Conference Journal. 6(3). 104–108. 1 indexed citations

11.

Ishigami, Masatoshi, Kazuhiko Hayashi, Takashi Honda, et al.. (2017). Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A‐Y93. Journal of Medical Virology. 90(4). 736–744. 2 indexed citations

12.

Matsumoto, Koji, Takashi Mimura, Tetsuya Ishikawa, et al.. (2017). Ultrasound-based logistic regression model LR2 versus magnetic resonance imaging for discriminating between benign and malignant adnexal masses: a prospective study. International Journal of Clinical Oncology. 23(3). 514–521. 11 indexed citations

13.

Kuzuya, Teiji, Masatoshi Ishigami, Yoji Ishizu, et al.. (2016). Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology. 91(5). 261–266. 9 indexed citations

14.

Isoda, Atsushi, Rie Saito, Tetsuya Ishikawa, et al.. (2016). Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study. International Journal of Hematology. 105(4). 478–484. 11 indexed citations

15.

Honda, Takashi, Masatoshi Ishigami, Hiroko Masuda, et al.. (2014). Effect of peginterferon alfa‐2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology. 30(2). 321–328. 7 indexed citations

16.

Hayashi, Kazuhiko, Yoshiaki Katano, Yoji Ishizu, et al.. (2014). Association of interleukin 28 B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness. Journal of Gastroenterology and Hepatology. 30(1). 178–183. 8 indexed citations

17.

Ishikawa, Tetsuya, et al.. (2013). Percutaneous coronary intervention with retrograde approach for chronic total occlusion after Kawasaki disease. 19(2). 188–192. 1 indexed citations

18.

Kuzuya, Teiji, Masatoshi Ishigami, Norihiro Imai, et al.. (2013). The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma. Kanzo. 54(7). 505–506. 1 indexed citations

19.

Ito, Hiroyasu, Kazuki Ando, Tetsuya Ishikawa, et al.. (2009). Role of TNF-α Produced by Nonantigen-Specific Cells in a Fulminant Hepatitis Mouse Model. The Journal of Immunology. 182(1). 391–397. 33 indexed citations

20.

Ayada, Minoru, Tetsuya Ishikawa, Akihiko Okumura, et al.. (2006). Cholestatic hepatic injury related to administration of sodium risedronate hydrate. A case report with distinctive histological findings. Kanzo. 47(1). 10–15. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact